Showing results (11-20 of 226) with videos related to

Sort By:
Pageof 23
Clinical Pharmacokinetics|July 1, 1997
The role of beta-glucuronidase in drug disposition and drug targeting in humansB Sperker, J T Backman, H K Kroemer
Clinical Pharmacology and Therapeutics|December 21, 2006
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevancePertti J Neuvonen, Mikko Niemi, Janne T Backman
Basic & Clinical Pharmacology & Toxicology|August 19, 2021
Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrelAleksi Tornio, Anne M Filppula, Janne T Backman
Clinical Pharmacology and Therapeutics|September 17, 2004
Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazoneMikko Niemi, Janne T Backman, Pertti J Neuvonen
European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery ... [Et Al] = Zeitschrift Fur Kinderchirurgie|October 16, 2009
Continuous double U-stitch gastrostomy in childrenT Backman, H Sjövie, C-M Kullendorff, et al.
British Journal of Clinical Pharmacology|April 2, 2005
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjectsJari J Lilja, Janne T Backman, Pertti J Neuvonen
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 21, 2006
Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactionsMarjo J Karjalainen, Pertti J Neuvonen, Janne T Backman
Clinical Pharmacology and Therapeutics|May 1, 1994
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazoleK T Olkkola, J T Backman, P J Neuvonen
European Journal of Clinical Pharmacology|March 1, 2015
Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosingSamuel Fanta, Mari Kinnunen, Janne T Backman, et al.
Pageof 23